Effects of repetitive administration of corticotropin-releasing hormone combined with lysine vasopressin on plasma adrenocorticotropin and cortisol levels in secondary adrenocortical insufficiency. 1990

J Fukata, and T Usui, and T Tsukada, and Y Nakai, and T Koh, and T Ishihara, and I Tanaka, and K Uchida, and T Yoshimasa, and R Nakano
Department of Internal Medicine, Kyoto University Faculty of Medicine, Japan.

To examine the functioning of the hypothalamo-pituitary-adrenocortical axis in secondary adrenocortical insufficiency, we administered 100 micrograms synthetic human CRH, iv, plus 10 U lysine-8-vasopressin (LVP), im, three times daily for 3 consecutive days. The changes in plasma ACTH and cortisol levels during the administration and the response to an insulin tolerance test (ITT) conducted before and after the administration were determined. In three patients with isolated ACTH deficiency, basal plasma ACTH and cortisol levels were undetectablly low, and there was no response noted in the ITT or during CRH-LVP administration throughout the observation period. In four patients with adrenocortical insufficiency who had undergone successful transsphenoidal microadenomectomy for Cushing's disease and in six patients who had undergone curative unilateral adrenalectomy for Cushing's syndrome, basal plasma ACTH levels were low, but responded considerably to both stimulation tests. Along with the 3 days of CRH-LVP stimulation, however, neither the peak nor the time-integrated ACTH response was significantly enhanced, because of the variability of the responses among the patients. Compared with the ACTH response on the last day of CRH-LVP stimulation, the subsequent ITT tended to induce a lower ACTH response in the post-Cushing's disease patients and a higher response in the post-Cushing's syndrome patients. Regarding the plasma cortisol levels, the basal, peak, and integrated responses tended to increase daily during CRH-LVP administration. Conversely, the ITT after repetitive CRH-LVP administration induced a higher cortisol response than the test before CRH-LVP administration in the post-Cushing's disease patients. No serious complications were noted in any of the patients during or after the treatment. The present findings indicate that 1) repetitive administration of CRH in combination with LVP is a safe and valuable provocation test to examine the pituitary ACTH reserve and the integrity of the pituitary-adrenocortical axis; 2) isolated ACTH deficiency is usually due to a defect at the pituitary level; 3) with respect to adrenocortical responsiveness, post-Cushing's disease patients show a better accumulation of the provocative effect than do post-Cushing's syndrome patients; and 4) both hypothalamic and pituitary dysfunction are responsible for adrenal hypofunction in patients after hypercortisolemia, but post-Cushing's syndrome patients (especially those with a short period of hypercortisolemia) appeared to have less impairment of hypothalamic ACTH-releasing activity than post-Cushing's disease patients.

UI MeSH Term Description Entries
D007031 Hypothalamus Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE. Lamina Terminalis,Preoptico-Hypothalamic Area,Area, Preoptico-Hypothalamic,Areas, Preoptico-Hypothalamic,Preoptico Hypothalamic Area,Preoptico-Hypothalamic Areas
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008236 Lypressin The porcine antidiuretic hormone (VASOPRESSINS). It is a cyclic nonapeptide that differs from ARG-VASOPRESSIN by one amino acid, containing a LYSINE at residue 8 instead of an ARGININE. Lys-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Lysine Vasopressin,Vasopressin, Lysine,8-Lysine Vasopressin,Diapid,Lys-Vasopressin,Lysyl Vasopressin,Postacton,8 Lysine Vasopressin,Lys Vasopressin,Vasopressin, 8-Lysine,Vasopressin, Lysyl
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010902 Pituitary Gland A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM. Hypophysis,Hypothalamus, Infundibular,Infundibular Stalk,Infundibular Stem,Infundibulum (Hypophysis),Infundibulum, Hypophyseal,Pituitary Stalk,Hypophyseal Infundibulum,Hypophyseal Stalk,Hypophysis Cerebri,Infundibulum,Cerebri, Hypophysis,Cerebrus, Hypophysis,Gland, Pituitary,Glands, Pituitary,Hypophyseal Stalks,Hypophyses,Hypophysis Cerebrus,Infundibular Hypothalamus,Infundibular Stalks,Infundibulums,Pituitary Glands,Pituitary Stalks,Stalk, Hypophyseal,Stalk, Infundibular,Stalks, Hypophyseal,Stalks, Infundibular
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol

Related Publications

J Fukata, and T Usui, and T Tsukada, and Y Nakai, and T Koh, and T Ishihara, and I Tanaka, and K Uchida, and T Yoshimasa, and R Nakano
March 1992, American journal of veterinary research,
J Fukata, and T Usui, and T Tsukada, and Y Nakai, and T Koh, and T Ishihara, and I Tanaka, and K Uchida, and T Yoshimasa, and R Nakano
August 1986, The Journal of clinical endocrinology and metabolism,
J Fukata, and T Usui, and T Tsukada, and Y Nakai, and T Koh, and T Ishihara, and I Tanaka, and K Uchida, and T Yoshimasa, and R Nakano
April 1984, The Journal of clinical endocrinology and metabolism,
J Fukata, and T Usui, and T Tsukada, and Y Nakai, and T Koh, and T Ishihara, and I Tanaka, and K Uchida, and T Yoshimasa, and R Nakano
May 1996, Domestic animal endocrinology,
J Fukata, and T Usui, and T Tsukada, and Y Nakai, and T Koh, and T Ishihara, and I Tanaka, and K Uchida, and T Yoshimasa, and R Nakano
March 1993, Journal of animal science,
J Fukata, and T Usui, and T Tsukada, and Y Nakai, and T Koh, and T Ishihara, and I Tanaka, and K Uchida, and T Yoshimasa, and R Nakano
December 1997, Neuroendocrinology,
J Fukata, and T Usui, and T Tsukada, and Y Nakai, and T Koh, and T Ishihara, and I Tanaka, and K Uchida, and T Yoshimasa, and R Nakano
July 1994, The Journal of clinical endocrinology and metabolism,
J Fukata, and T Usui, and T Tsukada, and Y Nakai, and T Koh, and T Ishihara, and I Tanaka, and K Uchida, and T Yoshimasa, and R Nakano
October 1985, Life sciences,
J Fukata, and T Usui, and T Tsukada, and Y Nakai, and T Koh, and T Ishihara, and I Tanaka, and K Uchida, and T Yoshimasa, and R Nakano
August 1994, The Journal of clinical endocrinology and metabolism,
J Fukata, and T Usui, and T Tsukada, and Y Nakai, and T Koh, and T Ishihara, and I Tanaka, and K Uchida, and T Yoshimasa, and R Nakano
January 1984, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!